2.76
-0.09
(-3.16%)
May 23 - Close
NYSEMKT
real-time data -
Disclaimer
Currency in USD
| Range | 2.70 - 2.80 |
| 52 week | 1.20 - 4.12 |
| Open | 2.80 |
| Vol / Avg. | 17,954.00/12,644.00 |
| Mkt cap | 75.87M |
| P/E | - |
| Div/yield | - |
| EPS | -0.95 |
| Shares | 27.49M |
| Beta | 0.07 |
| Inst. own | 8% |
Events
Apr 16, 2013
Q4 2012 ORAGENICS INC Earnings Release
|
More events from DailyFinance »
|
Key stats and ratios
| Q4 (Dec '12) | 2012 | |
| Net profit margin | -461.90% | -982.94% |
| Operating margin | -461.74% | -933.52% |
| EBITD margin | - | -927.88% |
| Return on average assets | -69.15% | -222.72% |
| Return on average equity | -79.52% | -2487.90% |
| Employees | 10 | - |
| Carbon Disclosure Rating | - | - |
Address
Suite 685, 3000 Bayport Dr
TAMPA, FL 33607
United States - Map
+1-813-2867900 (Phone)
+1-813-2867904 (Fax)
TAMPA, FL 33607
United States - Map
+1-813-2867900 (Phone)
+1-813-2867904 (Fax)
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Discussion Group - Google Finance
Volume delayed by 15 mins.
Advertisement
Description
Oragenics, Inc. is focused on the discovery, development and commercialization of a range of technologies associated with oral health, antibiotics and other general health benefits. The Company is developing and seeking partners or commercializing four products, including ProBiora3, LPT3-04, SMaRT Replacement Therapy and MU1140-S. The Company is focusing its efforts on growing its oral probiotic business both with its branded Evora products and through licensing and private label sales (with ProBiora3). Its SMaRT Replacement Therapy is designed to be a treatment applied to the teeth that has the potential to offer protection against dental caries, or tooth decay.
Officers and directors
| Frederick W. Telling Ph.D. | Independent Chairman of the Board | |
| John N. Bonfiglio Ph.D. | President, Chief Executive Officer, Director | |
| Michael Sullivan CPA | Chief Financial Officer, Treasurer, Secretary | |
| Alan W. Dunton M.D. | Independent Director | |
| Christine L. Koski | Independent Director | |
| Robert C. Koski | Independent Director | |
| Charles L. Pope CPA | Independent Director |